NASDAQ:ARQT
Arcutis Biotherapeutics Inc Stock News
$9.92
+0.440 (+4.64%)
At Close: May 22, 2024
Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture
03:09am, Wednesday, 31'st Jan 2024
Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture
Best Momentum Stocks to Buy for January 11th (Revised)
12:02pm, Friday, 12'th Jan 2024
ADMA and ARQT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 11, 2024.
New Strong Buy Stocks for January 11th
08:16am, Thursday, 11'th Jan 2024
ADMA, ARQT, PHR, OPRX and PHG have been added to the Zacks Rank #1 (Strong Buy) List on January 11, 2024.
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
12:47pm, Wednesday, 27'th Dec 2023
We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024 following signals of a stabilizing market.
Arcutis (ARQT) Up on FDA Nod for Zoryve in Seborrheic Dermatitis
01:32pm, Tuesday, 19'th Dec 2023
The FDA approves Arcutis' (ARQT) NDA for Zoryve topical foam 0.3% for treating seborrheic dermatitis in individuals nine years of age and above.
After Plunging -35.64% in 4 Weeks, Here's Why the Trend Might Reverse for Arcutis Biotherapeutics, Inc. (ARQT)
11:17am, Friday, 17'th Nov 2023
Arcutis Biotherapeutics, Inc. (ARQT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street
3 Biotech Stocks With Key Catalysts Coming in December
01:26pm, Wednesday, 15'th Nov 2023
Some of the most exciting opportunities can be found in biotech stocks. In fact, find one with a powerful catalyst just around the corner, and you can make a good deal of money.
Down -50.77% in 4 Weeks, Here's Why You Should You Buy the Dip in Arcutis Biotherapeutics, Inc. (ARQT)
11:21am, Wednesday, 01'st Nov 2023
Arcutis Biotherapeutics, Inc. (ARQT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street
Arcutis Biotherapeutics, Inc. (ARQT) Loses -51.27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:21am, Tuesday, 31'st Oct 2023
The heavy selling pressure might have exhausted for Arcutis Biotherapeutics, Inc. (ARQT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among W
Arcutis to Report Third Quarter 2023 Financial Results
04:00pm, Wednesday, 25'th Oct 2023
Arcutis will host a conference call and webcast at 8:30 a.m. ET on 11/3/2023 to report its third quarter financial results and provide a business update.
Arcutis Biotherapeutics shares sink on $100M stock sale
09:13am, Friday, 20'th Oct 2023
Arcutis Biotherapeutics Inc shares slid more than 18% in pre-market trading on Friday after the early commercial-stage medical dermatology company announced its intention to raise $100 million in a pu
Arcutis (ARQT) Up on FDA Nod for Zoryve Label Expansion
10:31am, Monday, 09'th Oct 2023
Arcutis (ARQT) gains on receiving FDA approval for label expansion of Zoryve (roflumilast) cream 0.3% to treat patients in the age group of 6-11 years with plaque psoriasis.
Arcutis (ARQT) Files sNDA for Zoryve in Atopic Dermatitis, Stock Up
09:46am, Wednesday, 13'th Sep 2023
Arcutis (ARQT) submits sNDA, seeking label expansion of Zoryve (roflumilast) cream 0.15% to treat patients with atopic dermatitis.
Why Shares of Arcutis Biotherapeutics Fell This Week
03:08pm, Thursday, 07'th Sep 2023
Arcutis' cash position is the biggest concern for investors. The company is already seeing strong sales from Zoryve, a little more than a year after it was launched.
Arcutis to Present at Upcoming Investor Conference
04:00pm, Tuesday, 05'th Sep 2023
WESTLAKE VILLAGE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-de
